Literature DB >> 29569032

2D speckle-tracking TTE-based quantitative classification of left ventricular myocardium in patients with hypertrophic cardiomyopathy by the presence or the absence of fibrosis and/or hypertrophy.

Nobusada Funabashi1, Hiroyuki Takaoka2, Koya Ozawa2, Masae Uehara3, Issei Komuro3, Yoshio Kobayashi2.   

Abstract

We used peak longitudinal strain (PLS) on TTE in HCM patients to differentiate LV myocardium (LVM) into the following 4 groups: group 1-no fibrosis or hypertrophy (≥ 13 mm), group 2-no fibrosis but hypertrophy evident, group 3-fibrosis present but without hypertrophy, and group 4-both fibrosis and hypertrophy. Seventeen HCM patients (13 males, 56 ± 16 years) underwent both 1.5 T CMR and TTE. On TTE, PLS (absolute values) for each LVM segment from 17 AHA-defined lesions was calculated. Of 289 LVM lesions, the numbers in each group, 1-4, were 156, 53, 39, and 41, respectively. PLS for LVM segments in group 1 (13.6 ± 6.4%) were significantly greater than those in group 2 (8.5 ±  4.9%, P < 0.001), group 3 (10.4 ± 5.0%, P = 0.006), and group 4 (7.1 ± 4.4%, P < 0.001). PLS for LVM segments in group 3 was significantly greater than those in group 4 (P = 0.016). However, significant differences in PLS in LVM between groups 2 and 3, and between 2 and 4 were not observed. Using regional PLS, we demonstrate successful differentiation of LVM in HCM patients for group 1 (LVM with zero fibrosis or hypertrophy) from LVM belonging to groups 2-4 and we also demonstrate successful differentiation of LVM with fibrosis present but without hypertrophy from LVM with both fibrosis and hypertrophy. However, it is not possible to differentiate between LVM with no fibrosis but hypertrophy evident and those with fibrosis present but without hypertrophy and also between LVM with no fibrosis but hypertrophy evident and those with both fibrosis and hypertrophy. Our findings have significant implications for the management of HCM patients.

Entities:  

Keywords:  Fibrosis; Hypertrophic cardiomyopathy; Hypertrophy; Late enhancement; Left ventricular myocardium; Magnetic resonance imaging; Peak longitudinal strain; Speckle-tracking transthoracic echocardiography

Mesh:

Year:  2018        PMID: 29569032     DOI: 10.1007/s00380-018-1155-z

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  23 in total

Review 1.  Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association.

Authors:  Manuel D Cerqueira; Neil J Weissman; Vasken Dilsizian; Alice K Jacobs; Sanjiv Kaul; Warren K Laskey; Dudley J Pennell; John A Rumberger; Thomas Ryan; Mario S Verani
Journal:  Circulation       Date:  2002-01-29       Impact factor: 29.690

2.  Investigation of global and regional myocardial mechanics with 3-dimensional speckle tracking echocardiography and relations to hypertrophy and fibrosis in hypertrophic cardiomyopathy.

Authors:  Jose Angel Urbano-Moral; Ethan J Rowin; Martin S Maron; Andrew Crean; Natesa G Pandian
Journal:  Circ Cardiovasc Imaging       Date:  2013-11-25       Impact factor: 7.792

Review 3.  Speckle tracking echocardiography - Quo Vadis?

Authors:  Masaaki Uematsu
Journal:  Circ J       Date:  2015-03-13       Impact factor: 2.993

4.  Normal range of left ventricular 2-dimensional strain: Japanese Ultrasound Speckle Tracking of the Left Ventricle (JUSTICE) study.

Authors:  Kiyohiro Takigiku; Masaaki Takeuchi; Chisato Izumi; Satoshi Yuda; Konomi Sakata; Nobuyuki Ohte; Kazuaki Tanabe; Satoshi Nakatani
Journal:  Circ J       Date:  2012-07-20       Impact factor: 2.993

5.  Late gadolinium enhancement and prognosis of hypertrophic cardiomyopathy.

Authors:  Hajime Sakuma
Journal:  Circ J       Date:  2014-03-10       Impact factor: 2.993

6.  Prognostic predictive value of gene mutations in Japanese patients with hypertrophic cardiomyopathy.

Authors:  Ayako Chida; Kei Inai; Hiroki Sato; Eriko Shimada; Tsutomu Nishizawa; Mitsuyo Shimada; Michiko Furutani; Yoshiyuki Furutani; Yoichi Kawamura; Masaya Sugimoto; Jun Ishihara; Masako Fujiwara; Takashi Soga; Masatoshi Kawana; Shinya Fuji; Shigeru Tateno; Kenji Kuraishi; Shigetoyo Kogaki; Mitsuhiro Nishimura; Mamoru Ayusawa; Fukiko Ichida; Hirokuni Yamazawa; Rumiko Matsuoka; Shigeaki Nonoyama; Toshio Nakanishi
Journal:  Heart Vessels       Date:  2016-11-24       Impact factor: 2.037

7.  Left ventricular strain and transmural distribution of structural remodeling in hypertensive heart disease.

Authors:  Tomoko Ishizu; Yoshihiro Seo; Yuri Kameda; Ryo Kawamura; Taizou Kimura; Nobutake Shimojo; Dongzhu Xu; Nobuyuki Murakoshi; Kazutaka Aonuma
Journal:  Hypertension       Date:  2014-01-06       Impact factor: 10.190

8.  Native T1 and ECV of Noninfarcted Myocardium and Outcome in Patients With Coronary Artery Disease.

Authors:  Valentina O Puntmann; Gerry Carr-White; Andrew Jabbour; Chung-Yao Yu; Rolf Gebker; Sebastian Kelle; Andreas Rolf; Sabine Zitzmann; Elif Peker; Tommaso D'Angelo; Faraz Pathan; Silvia Valbuena; Rocio Hinojar; Christophe Arendt; Jagat Narula; Eva Herrmann; Andreas M Zeiher; Eike Nagel
Journal:  J Am Coll Cardiol       Date:  2018-02-20       Impact factor: 24.094

9.  Diagnostic accuracy of CT for the detection of left ventricular myocardial fibrosis in various myocardial diseases.

Authors:  Hiroyuki Takaoka; Nobusada Funabashi; Masae Uehara; Yasunori Iida; Yoshio Kobayashi
Journal:  Int J Cardiol       Date:  2016-11-09       Impact factor: 4.164

10.  Impact of Afterload Increase on Left Ventricular Myocardial Deformation Indices.

Authors:  Patricia Reant; Alexandre Metras; Dominique Detaille; Annabel Reynaud; Philippe Diolez; Beatrice Jaspard-Vinassa; Raymond Roudaut; Alexandre Ouattara; Laurent Barandon; Pierre Dos Santos; Stephane Lafitte
Journal:  J Am Soc Echocardiogr       Date:  2016-10-14       Impact factor: 5.251

View more
  1 in total

Review 1.  Fibrosis in hypertrophic cardiomyopathy: role of novel echo techniques and multi-modality imaging assessment.

Authors:  Efstathios D Pagourelias; Georgios M Alexandridis; Vassilios P Vassilikos
Journal:  Heart Fail Rev       Date:  2021-05-15       Impact factor: 4.214

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.